Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.

Autor: Mariani P; Department of Surgery, Institut Curie, Paris, France., Torossian N; Department of Medical Oncology, Institut Curie, Paris, France., van Laere S; Faculty of Medicine and Health Sciences, University of Antwerp-MIPRO Center for Oncological Research (CORE) - TCRU, GZA Sint-Augustinus, Antwerp, Belgium., Vermeulen P; Faculty of Medicine and Health Sciences, University of Antwerp-MIPRO Center for Oncological Research (CORE) - TCRU, GZA Sint-Augustinus, Antwerp, Belgium., de Koning L; Department of Translational Research, Institut Curie, Paris, France., Roman-Roman S; Department of Translational Research, Institut Curie, Paris, France., Lantz O; Laboratoire d'immunologie clinique, Institut Curie, Paris, France.; Centre d'investigation Clinique en Biothérapie, Institut Curie (CIC-BT1428), Paris, France.; INSERM U932, PSL University, Institut Curie, Paris, France., Rodrigues M; Department of Medical Oncology, Institut Curie, Paris, France.; Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par la Ligue Nationale Contre le Cancer, Institut Curie, Paris, France., Stern MH; Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par la Ligue Nationale Contre le Cancer, Institut Curie, Paris, France., Gardrat S; Department of Pathology, Institut Curie, Paris, France., Lesage L; Department of Pathology, Institut Curie, Paris, France., Champenois G; Department of Pathology, Institut Curie, Paris, France., Nicolas A; Department of Pathology, Institut Curie, Paris, France., Matet A; Department of Ophthalmology, Institut Curie, Paris, France.; Université de Paris Cité UFR de Médecine, Paris, France., Cassoux N; Department of Ophthalmology, Institut Curie, Paris, France.; Université de Paris Cité UFR de Médecine, Paris, France., Servois V; Department of Radiology, Institut Curie, Paris, France., Romano E; Department of Medical Oncology, Institut Curie, Paris, France., Piperno-Neumann S; Department of Medical Oncology, Institut Curie, Paris, France., Lugassy C; Department of Translational Research, Institut Curie, Paris, France., Barnhill R; Department of Translational Research, Institut Curie, Paris, France. raymond.barnhill@curie.fr.; Université de Paris Cité UFR de Médecine, Paris, France. raymond.barnhill@curie.fr.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2023 Sep; Vol. 129 (5), pp. 772-781. Date of Electronic Publication: 2023 Jul 13.
DOI: 10.1038/s41416-023-02331-w
Abstrakt: Background: The immune landscape of uveal melanoma liver metastases (UMLM) has not been sufficiently studied.
Methods: Immune cell infiltrates (ICIs), PD-1 and PD-L1 were characterised in 62 UMLM and 28 primary uveal melanomas (PUM). ICI, PD-1 and PD-L1 were scored as: (1) % tumoral area occupied by tumour-infiltrating lymphocytes or macrophages (TILs, TIMs) and (2) % perTumoral (perT) area. ICIs and other variables including histopathologic growth patterns (HGPs), replacement and desmoplastic, of UMLM were analysed for their prognostic value.
Results: ICIs recognised by haematoxylin-eosin-saffron (HES) and IHC (e.g., T cells (CD3), B cells (CD20). Macrophages (CD68), (CD163), were primarily localised to the perT region in PUM and UMLM and were more conspicuous in UMLM. HES, CD3, CD4, FoxP3, CD8, CD20, PD-1 TILs were scant (<5%). TIMs were more frequent, particularly in UMLM than in PUM. Both CD68+ TIMs and HGPs remained significant on multivariate analysis, influencing overall (OS) and metastasis-specific overall survival (MSOS). CD68 + , CD163+ and CD20+ perT infiltrates in UMLM predicted increased OS and MSOS on univariate analysis.
Conclusions: TILs and PD-L1 have no predictive value in PUM or UMLM. CD68+ and CD163+TIMs, CD20+ perT lymphocytes, and HGPs are important prognostic factors in UMLMs.
(© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: